NeuroPhage Pharmaceuticals is developing drugs based on the breakthrough GAIM (general amyloid interaction motif) platform that can target multiple misfolded proteins for the treatment of a broad range of neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple orphan indications (HD, ALS, CJD, PSP, MSA).
GAIM-based therapies use a novel mechanism to:
- Target a broad spectrum of misfolded proteins (Aβ, tau, α-synuclein, prion) by recognizing a common amyloid protein conformation
- Bind, dissociate and prevent formation of misfolded protein assemblies involved in pathology of neurodegenerative diseases
- Target key stages of amyloid assembly (oligomers to fibrils to plaques)
- Block cell-to-cell spread of misfolded proteins